Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | TFEB | P19484 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672769 | 1.00 | KDM4E (0.45) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL11939336 | 0.87 | KMT2A (0.58) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL11939429 | 0.87 | KMT2A (0.58) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL11939024 | 0.86 | KMT2A (0.45) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL11939335 | 0.86 | KMT2A (0.45) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL5487013 | 0.84 | NFE2L2 (0.45) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL5487009 | 0.84 | NFE2L2 (0.45) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL11338676 | 0.83 | PTGDR2 (0.47) | KDM4EKMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL19719742 | 0.82 | KMT2A (0.44) | KDM4EKMT2AMEN1NFE2L2TFEB | |
| SCHEMBL17863709 | 0.82 | KMT2A (0.44) | KDM4EKMT2AMEN1NFE2L2TFEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528685-B1 | PROCESS FOR PREPARATION OF RUTHENIUM-BASED CARBENE CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS | UMICORE AG & CO KG (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-9278345-B2 | Process for preparation of ruthenium-based carbene catalysts with chelating alkylidene ligands | UMICORE AG & CO. KG (DE) | 2016-03-08 | — | — | US | disclosed |
| US-20130035494-A1 | Process for Preparation of Ruthenium-Based Carbene Catalysts with Chelating Alkylidene Ligands | GHENT UNIVERSITY (BE) | 2013-02-07 | — | — | US | disclosed |
| EP-2528685-A1 | PROCESS FOR PREPARATION OF RUTHENIUM-BASED CARBENE CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS | Umicore AG & Co. KG (DE) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011091980-A1 | PROCESS FOR PREPARATION OF RUTHENIUM-BASED CARBENE CATALYSTS WITH CHELATING ALKYLIDENE LIGANDS | UMICORE AG & CO. KG (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035494-A1 | Process for Preparation of Ruthenium-Based Carbene Catalysts with Chelating Alkylidene Ligands | SPR, SRPRA, SLC7A11 | KDM4E 3357/4885KMT2A 1753/4885MEN1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.